Study of relationship between papillary thyroid carcinoma and Hashimoto thyroiditis_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

LIU Hua , QIAN Changlin ,  QIU Weiqing

Department of General Surgery (South Campus), Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 201120, P. R. China;

Corresponding?author：

QIU Weiqing, Email: housman111@aliyun.com

Keywords：

papillary thyroid cancer; Hashimoto thyroiditis; correlation

DOI：

10.7507/1007-9424.202208077

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize the progress of research about the relationship between papillary thyroid carcinoma (PTC) and Hashimoto’s thyroiditis (HT). Method The relevant literatures at home and abroad in recent years about this topic were collected and analyzed. Results Comprehensive literature reviewed, combined with the author's clinical research results, PTC and HT were indeed closely related, or there was a certain causal link. HT and PTC might both come from the same embryonic stem cells. HT was an autoimmune thyroid disease caused by abnormal immune response, and might be a triggering factor of PTC. Meanwhile, lymphocyte infiltration might play a certain protective role in anti-tumor effect. RET chromosome rearrangement, RAS point mutation and BRAF gene mutation might activate mitogen-activated protein kinase (MAPK) pathway, especially in PTC cases with HT in which RET chromosome rearrangement was more common. In the future, selective targeted therapy aiming at the activation of RET/RAS/BRAF/MAPK pathway was a promising treatment especially in advanced PTC cases. Conclusions The correlation between PTC and HT is not fully clarified. HT is a potential risk factor for PTC but the cases of PTC with HT have a better prognosis. More prospective studies will help to further clarify the correlation between two diseases.

Citation： LIU Hua, QIAN Changlin, QIU Weiqing. Study of relationship between papillary thyroid carcinoma and Hashimoto thyroiditis. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2023, 30(3): 374-378. doi: 10.7507/1007-9424.202208077 Copy

1.	Xu JY, Ding K, Mu L, et al. Hashimoto’s thyroiditis: a “double-edged sword” in thyroid carcinoma. Front Endocrinol (Lausanne), 2022, 13: 801925. doi: 10.3389/fendo.2022.801925.
2.	Tang QZ, Pan WY, Peng LY. Association between Hashimoto thyroiditis and clinical outcomes of papillary thyroid carcinoma: A meta-analysis. PLoS One, 2022, 17(6): e0269995. doi: 10.1371/journal.pone.0269995.
3.	Coelho M, Raposo L, Goodfellow BJ, et al. The potential of metabolomics in the diagnosis of thyroid cancer. Int J Mol Sci, 2020, 21(15): 5272. doi: 10.3390/ijms21155272.
4.	Weetman AP. An update on the pathogenesis of Hashimoto’s thyroiditis. J Endocrinol Invest, 2021, 44(5): 883-890.
5.	Giuffrida D, Giuffrida R, Puliafito I, et al. Thyroidectomy as treatment of choice for differentiated thyroid cancer. Int J Surg Oncol, 2019, 2019: 2715260. doi: 10.1155/2019/2715260.
6.	Nguyen M, He G, Lam KY. Clinicopathological and molecular features of secondary cancer (metastasis) to the thyroid and advances in management. Int J Mol Sci, 2022, 23(6): 3242. doi: 10.3390/ijms23063242.
7.	張穎超, 鄧先兆, 郭伯敏, 等. 甲狀腺癌分子診斷和靶向治療的新進展及應用. 中華內分泌外科雜志, 2021, 15(5): 546-550.
8.	Ruiz EML, Niu T, Zerfaoui M, et al. A novel gene panel for prediction of lymph-node metastasis and recurrence in patients with thyroid cancer. Surgery, 2020, 167(1): 73-79.
9.	王亞茜, 王曉武, 馬志軍. 甲狀腺微小乳頭狀癌術前診斷的研究進展. 臨床醫學進展, 2022, 12(6): 4983-4988.
10.	Zhou LG, Chen G, Sheng L, et al. Influence factors for lymph node metastasis in papillary thyroid carcinoma: Hashimoto’s thyroiditis has a weak effect on central or lateral lymph node metastasis. Cancer Manag Res, 2021, 13: 3953-3961.
11.	Zhang X, Zhang X, Chang Z, et al. Correlation analyses of thyroid-stimulating hormone and thyroid autoantibodies with differentiated thyroid cancer. J Buon, 2018, 23(5): 1467-1471.
12.	Rashid FA, Munkhdelger J, Fukuoka J, et al. Prevalence of BRAF^V600E mutation in asian series of papillary thyroid carcinoma—a contemporary systematic review. Gland Surg, 2020, 9(5): 1878-1900.
13.	高旭, 喻慶安, 閆肖, 等. 分化型甲狀腺癌血液標志物的研究現狀及進展. 中國普外基礎與臨床雜志, 2022, 29(1): 118-123.
14.	Hamad MA, Lasrado S, Albarbari HS, et al. Research productivity in the genetics of papillary thyroid carcinoma (1991-2020): a bibliometric analysis. Acta Biomed, 2022, 93(3): e2022086. doi: 10.23750/abm.v93i3.12576.
15.	Landa I, Pozdeyev N, Knauf JA, et al. Genetics of human thyroid cancer cell lines-response. Clin Cancer Res, 2019, 25(22): 6883-6884.
16.	Wang CW, Lee YC, Calista E, et al. A benchmark for comparing precision medicine methods in thyroid cancer diagnosis using tissue microarrays. Bioinformatics, 2018, 34(10): 1767-1773.
17.	Singh A, Ham J, Po JW, et al. The genomic landscape of thyroid cancer tumourigenesis and implications for immunotherapy. Cells, 2021, 10(5): 1082. doi: 10.3390/cells10051082.
18.	Ma HZ, Wang R, Fang JG, et al. A meta-analysis evaluating the relationship between B-type Raf kinase mutation and cervical lymphatic metastasis in papillary thyroid cancer. Medicine (Baltimore), 2020, 99(5): e18917. doi: 10.1097/MD.0000000000018917.
19.	Liang J, Cai W, Feng D, et al. Genetic landscape of papillary thyroid carcinoma in the Chinese population. J Pathol, 2018, 244(2): 215-226.
20.	Banizs AB, Silverman JF. The utility of combined mutation analysis and microRNA classification in reclassifying cancer risk of cytologically indeterminate thyroid nodules. Diagn Cytopathol, 2019, 47(4): 268-274.
21.	Agarwal S, Bychkov A, Jun CK. Emerging biomarkers in thyroid practice and research. Cancers (Basel), 2022, 14(1): 204. doi: 10.3390/cancers14010204.
22.	奧偉, 殷德濤. 運用生物信息學篩選甲狀腺乳頭狀癌生物靶點. 中國普外基礎與臨床雜志, 2021, 28(3): 329-335.
23.	Lan XB, Bao H, Ge XY, et al. Genomic landscape of metastatic papillary thyroid carcinoma and novel biomarkers for predicting distant metastasis. Cancer Sci, 2020, 111(6): 2163-2173.
24.	Gerber TS, Schad A, Hartmann N, et al. Targeted next-generation sequencing of cancer genes in poorly differentiated thyroid cancer. Endocr Connect, 2018, 7(1): 47-55.
25.	龐長安, 朱洪海, 李雪娟, 等. 瞬時受體蛋白通道 C5 和 miR-320a 在甲狀腺癌中的表達及臨床意義. 中國普外基礎與臨床雜志, 2021, 28(9): 1165-1170.
26.	Rangel-Pozzo A, Sisdelli L, Isabel V M, et al. Genetic landscape of papillary thyroid carcinoma and nuclear architecture: an overview comparing pediatric and adult populations. Cancers (Basel), 2020 , 12(11): 3146. doi: 10.3390/cancers12113146.
27.	Xing MZ, Alzahrani AS, Carson KA, et al. Association between BRAF^V600E mutation and mortality in patients with papillary thyroid cancer. JAMA, 2013, 309: 1493-1501.
28.	Pelaz AC, Shah JP, Hernandez-Prera JC, et al. Papillary thyroid cancer—aggressive variants and impact on management: a narrative review. Adv Ther, 2020, 37(7): 3112-3128.
29.	Howell GM, Nikiforova MN, Carty SE, et al. BRAF^V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann Surg Oncol, 2013, 20(1): 47-52.
30.	李微微, 宋根, 張偉. KRTAP5-AS1 負調控miR-335對甲狀腺癌細胞增殖、遷移及凋亡的影響. 中國免疫學雜志, 2022, 37(6): 708-714.
31.	Liao YN, Hua YJ, Zhang CL, et al. CRSP8 promotes thyroid cancer progression by antagonizing IKKα-induced cell differentiation. Cell Death Differ, 2021, 28(4): 1347-1363.
32.	Li SP, Li SL, Lin M, et al. Interleukin-17 and vascular endothelial growth factor: new biomarkers for the diagnosis of papillary thyroid carcinoma in patients with Hashimoto’s thyroiditis. J Int Med Res, 2022, 50(1): 03000605211067121. doi: 10.1177/03000605211067121.
33.	Choe J, Baek JH, Park HS, et al. Core needle biopsy of thyroid nodules: outcomes and safety from a large single-center single-operator study. Acta Radiol, 2018, 59(8): 924-931.
34.	Carrillo JF, Vázquez-Romo R, Ramírez-Ortega MC, et al. Prognostic impact of direct ¹³¹I therapy after detection of biochemical recurrence in intermediate or high-risk differentiated thyroid cancer: a retrospective cohort study. Front Endocrinol (Lausanne), 2019, 10: 737. doi: 10.3389/fendo.2019.00737.
35.	Ak?n ?, Yazgan Aksoy D, Ak?n S, et al. Prediction of central lymph node metastasis in patients with thyroid papillary microcarcinoma. Turk J Med Sci, 2017, 47(6): 1723-1727.
36.	Papaioannou M, Chorti AG, Chatzikyriakidou A, et al. MicroRNAs in papillary thyroid cancer: What is new in diagnosis and treatment. Front Oncol, 2021, 11: 755097. doi: 10.3389/fonc.2021.755097.
37.	Hu YF, Feng WW, ChenHH, et al. Effect of selenium on thyroid autoimmunity and regulatory T cells in patients with Hashimoto’s thyroiditis: A prospective randomized-controlled trial. Clin Transl Sci, 2021, 14(4): 1390-1402.
38.	Zhao N, Liu X, Wu C, et al. Changes in Treg numbers and activity in papillary thyroid carcinoma with and without Hashimoto’s thyroiditis. J Int Med Res, 2020, 48(4): 0300060520919222. doi: 10.1177/0300060520919222.
39.	Zhu F, Shen YB, Li FQ, et al. The effects of Hashimoto thyroiditis on lymph node metastases in unifocal and multifocal papillary thyroid carcinoma: a retrospective Chinese cohort study. Medicine (Baltimore), 2016, 95(6): e2674. doi: 10.1097/MD.0000000000002674.
40.	程維剛, 劉九洲, 張海鴿, 等. 甲狀腺癌中微小RNA-146b-5p表達上調通過靶向Smad4促進癌細胞增殖. 中華實驗外科雜志, 2022, 39(2): 257-260.
41.	Pani F, Caria P, Yasuda Y, et al. The immune landscape of papillary thyroid cancer in the context of autoimmune thyroiditis. Cancers (Basel) 2022 Sep; 14(17): 4287.
42.	Hu XJ, Wang XY, Liang Y, et al. Cancer risk in Hashimoto’s thyroiditis: a systematic review and meta-analysis. Front Endocrinol (Lausanne), 2022, 13: 937871. doi: 10.3389/fendo.2022.937871.
43.	Mohammad AJ, Shilpa T, Sriram G, et al. Novel targeted therapies for metastatic thyroid cancer—a comprehensive review. Cancers (Basel), 2020 , 12(8): 2104. doi: 10.3390/cancers12082104.

1. Xu JY, Ding K, Mu L, et al. Hashimoto’s thyroiditis: a “double-edged sword” in thyroid carcinoma. Front Endocrinol (Lausanne), 2022, 13: 801925. doi: 10.3389/fendo.2022.801925.
2. Tang QZ, Pan WY, Peng LY. Association between Hashimoto thyroiditis and clinical outcomes of papillary thyroid carcinoma: A meta-analysis. PLoS One, 2022, 17(6): e0269995. doi: 10.1371/journal.pone.0269995.
3. Coelho M, Raposo L, Goodfellow BJ, et al. The potential of metabolomics in the diagnosis of thyroid cancer. Int J Mol Sci, 2020, 21(15): 5272. doi: 10.3390/ijms21155272.
4. Weetman AP. An update on the pathogenesis of Hashimoto’s thyroiditis. J Endocrinol Invest, 2021, 44(5): 883-890.
5. Giuffrida D, Giuffrida R, Puliafito I, et al. Thyroidectomy as treatment of choice for differentiated thyroid cancer. Int J Surg Oncol, 2019, 2019: 2715260. doi: 10.1155/2019/2715260.
6. Nguyen M, He G, Lam KY. Clinicopathological and molecular features of secondary cancer (metastasis) to the thyroid and advances in management. Int J Mol Sci, 2022, 23(6): 3242. doi: 10.3390/ijms23063242.
7. 張穎超, 鄧先兆, 郭伯敏, 等. 甲狀腺癌分子診斷和靶向治療的新進展及應用. 中華內分泌外科雜志, 2021, 15(5): 546-550.
8. Ruiz EML, Niu T, Zerfaoui M, et al. A novel gene panel for prediction of lymph-node metastasis and recurrence in patients with thyroid cancer. Surgery, 2020, 167(1): 73-79.
9. 王亞茜, 王曉武, 馬志軍. 甲狀腺微小乳頭狀癌術前診斷的研究進展. 臨床醫學進展, 2022, 12(6): 4983-4988.
10. Zhou LG, Chen G, Sheng L, et al. Influence factors for lymph node metastasis in papillary thyroid carcinoma: Hashimoto’s thyroiditis has a weak effect on central or lateral lymph node metastasis. Cancer Manag Res, 2021, 13: 3953-3961.
11. Zhang X, Zhang X, Chang Z, et al. Correlation analyses of thyroid-stimulating hormone and thyroid autoantibodies with differentiated thyroid cancer. J Buon, 2018, 23(5): 1467-1471.
12. Rashid FA, Munkhdelger J, Fukuoka J, et al. Prevalence of BRAF^V600E mutation in asian series of papillary thyroid carcinoma—a contemporary systematic review. Gland Surg, 2020, 9(5): 1878-1900.
13. 高旭, 喻慶安, 閆肖, 等. 分化型甲狀腺癌血液標志物的研究現狀及進展. 中國普外基礎與臨床雜志, 2022, 29(1): 118-123.
14. Hamad MA, Lasrado S, Albarbari HS, et al. Research productivity in the genetics of papillary thyroid carcinoma (1991-2020): a bibliometric analysis. Acta Biomed, 2022, 93(3): e2022086. doi: 10.23750/abm.v93i3.12576.
15. Landa I, Pozdeyev N, Knauf JA, et al. Genetics of human thyroid cancer cell lines-response. Clin Cancer Res, 2019, 25(22): 6883-6884.
16. Wang CW, Lee YC, Calista E, et al. A benchmark for comparing precision medicine methods in thyroid cancer diagnosis using tissue microarrays. Bioinformatics, 2018, 34(10): 1767-1773.
17. Singh A, Ham J, Po JW, et al. The genomic landscape of thyroid cancer tumourigenesis and implications for immunotherapy. Cells, 2021, 10(5): 1082. doi: 10.3390/cells10051082.
18. Ma HZ, Wang R, Fang JG, et al. A meta-analysis evaluating the relationship between B-type Raf kinase mutation and cervical lymphatic metastasis in papillary thyroid cancer. Medicine (Baltimore), 2020, 99(5): e18917. doi: 10.1097/MD.0000000000018917.
19. Liang J, Cai W, Feng D, et al. Genetic landscape of papillary thyroid carcinoma in the Chinese population. J Pathol, 2018, 244(2): 215-226.
20. Banizs AB, Silverman JF. The utility of combined mutation analysis and microRNA classification in reclassifying cancer risk of cytologically indeterminate thyroid nodules. Diagn Cytopathol, 2019, 47(4): 268-274.
21. Agarwal S, Bychkov A, Jun CK. Emerging biomarkers in thyroid practice and research. Cancers (Basel), 2022, 14(1): 204. doi: 10.3390/cancers14010204.
22. 奧偉, 殷德濤. 運用生物信息學篩選甲狀腺乳頭狀癌生物靶點. 中國普外基礎與臨床雜志, 2021, 28(3): 329-335.
23. Lan XB, Bao H, Ge XY, et al. Genomic landscape of metastatic papillary thyroid carcinoma and novel biomarkers for predicting distant metastasis. Cancer Sci, 2020, 111(6): 2163-2173.
24. Gerber TS, Schad A, Hartmann N, et al. Targeted next-generation sequencing of cancer genes in poorly differentiated thyroid cancer. Endocr Connect, 2018, 7(1): 47-55.
25. 龐長安, 朱洪海, 李雪娟, 等. 瞬時受體蛋白通道 C5 和 miR-320a 在甲狀腺癌中的表達及臨床意義. 中國普外基礎與臨床雜志, 2021, 28(9): 1165-1170.
26. Rangel-Pozzo A, Sisdelli L, Isabel V M, et al. Genetic landscape of papillary thyroid carcinoma and nuclear architecture: an overview comparing pediatric and adult populations. Cancers (Basel), 2020 , 12(11): 3146. doi: 10.3390/cancers12113146.
27. Xing MZ, Alzahrani AS, Carson KA, et al. Association between BRAF^V600E mutation and mortality in patients with papillary thyroid cancer. JAMA, 2013, 309: 1493-1501.
28. Pelaz AC, Shah JP, Hernandez-Prera JC, et al. Papillary thyroid cancer—aggressive variants and impact on management: a narrative review. Adv Ther, 2020, 37(7): 3112-3128.
29. Howell GM, Nikiforova MN, Carty SE, et al. BRAF^V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann Surg Oncol, 2013, 20(1): 47-52.
30. 李微微, 宋根, 張偉. KRTAP5-AS1 負調控miR-335對甲狀腺癌細胞增殖、遷移及凋亡的影響. 中國免疫學雜志, 2022, 37(6): 708-714.
31. Liao YN, Hua YJ, Zhang CL, et al. CRSP8 promotes thyroid cancer progression by antagonizing IKKα-induced cell differentiation. Cell Death Differ, 2021, 28(4): 1347-1363.
32. Li SP, Li SL, Lin M, et al. Interleukin-17 and vascular endothelial growth factor: new biomarkers for the diagnosis of papillary thyroid carcinoma in patients with Hashimoto’s thyroiditis. J Int Med Res, 2022, 50(1): 03000605211067121. doi: 10.1177/03000605211067121.
33. Choe J, Baek JH, Park HS, et al. Core needle biopsy of thyroid nodules: outcomes and safety from a large single-center single-operator study. Acta Radiol, 2018, 59(8): 924-931.
34. Carrillo JF, Vázquez-Romo R, Ramírez-Ortega MC, et al. Prognostic impact of direct ¹³¹I therapy after detection of biochemical recurrence in intermediate or high-risk differentiated thyroid cancer: a retrospective cohort study. Front Endocrinol (Lausanne), 2019, 10: 737. doi: 10.3389/fendo.2019.00737.
35. Ak?n ?, Yazgan Aksoy D, Ak?n S, et al. Prediction of central lymph node metastasis in patients with thyroid papillary microcarcinoma. Turk J Med Sci, 2017, 47(6): 1723-1727.
36. Papaioannou M, Chorti AG, Chatzikyriakidou A, et al. MicroRNAs in papillary thyroid cancer: What is new in diagnosis and treatment. Front Oncol, 2021, 11: 755097. doi: 10.3389/fonc.2021.755097.
37. Hu YF, Feng WW, ChenHH, et al. Effect of selenium on thyroid autoimmunity and regulatory T cells in patients with Hashimoto’s thyroiditis: A prospective randomized-controlled trial. Clin Transl Sci, 2021, 14(4): 1390-1402.
38. Zhao N, Liu X, Wu C, et al. Changes in Treg numbers and activity in papillary thyroid carcinoma with and without Hashimoto’s thyroiditis. J Int Med Res, 2020, 48(4): 0300060520919222. doi: 10.1177/0300060520919222.
39. Zhu F, Shen YB, Li FQ, et al. The effects of Hashimoto thyroiditis on lymph node metastases in unifocal and multifocal papillary thyroid carcinoma: a retrospective Chinese cohort study. Medicine (Baltimore), 2016, 95(6): e2674. doi: 10.1097/MD.0000000000002674.
40. 程維剛, 劉九洲, 張海鴿, 等. 甲狀腺癌中微小RNA-146b-5p表達上調通過靶向Smad4促進癌細胞增殖. 中華實驗外科雜志, 2022, 39(2): 257-260.
41. Pani F, Caria P, Yasuda Y, et al. The immune landscape of papillary thyroid cancer in the context of autoimmune thyroiditis. Cancers (Basel) 2022 Sep; 14(17): 4287.
42. Hu XJ, Wang XY, Liang Y, et al. Cancer risk in Hashimoto’s thyroiditis: a systematic review and meta-analysis. Front Endocrinol (Lausanne), 2022, 13: 937871. doi: 10.3389/fendo.2022.937871.
43. Mohammad AJ, Shilpa T, Sriram G, et al. Novel targeted therapies for metastatic thyroid cancer—a comprehensive review. Cancers (Basel), 2020 , 12(8): 2104. doi: 10.3390/cancers12082104.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Study of relationship between papillary thyroid carcinoma and Hashimoto thyroiditis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content